- Home
- SABS
as 12-18-2024 4:00pm EST
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | MIAMI BEACH |
| Market Cap: | 23.9M | IPO Year: | N/A |
| Target Price: | $12.40 | AVG Volume (30 days): | 83.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.28 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.16 - $7.70 | Next Earning Date: | 11-06-2024 |
| Revenue: | $1,512,723 | Revenue Growth: | -63.06% |
| Revenue Growth (this year): | -39.66% | Revenue Growth (next year): | -24.50% |
Latest SAB Biotherapeutics Inc. News
SABS Breaking Stock News: Dive into SABS Ticker-Specific Updates for Smart Investing
TipRanks
a month ago
These 2 “Strong Buy” Penny Stocks Are Set to Triple (or more), Say Analysts
Simply Wall St.
a month ago
SAB Biotherapeutics Third Quarter 2024 Earnings: US$1.12 loss per share (vs US$0.97 loss in 3Q 2023)
GlobeNewswire
a month ago
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
GlobeNewswire
2 months ago
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
Simply Wall St.
3 months ago
SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely
GlobeNewswire
3 months ago
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
GlobeNewswire
3 months ago
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
GlobeNewswire
3 months ago
SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting
Compare SABS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SABS SAB Biotherapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.